Calcimimetics: A remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 4, 2005, Pages 355-360

  Goodman, William G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Calcimimetic agents; Calcium sensing receptor; Hyperparathyroidism; Parathyroid gland hyperplasia; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; STEROL DERIVATIVE; VITAMIN D;

CALCIUM METABOLISM; CALCIUM SIGNALING; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG EFFECT; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HYPERPARATHYROIDISM; MOLECULAR MECHANICS; PARATHYROID FUNCTION; PARATHYROID HYPERPLASIA; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 20844446785     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000172722.52499.71     Document Type: Review

References (38)

1. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179-1187. Results from an international registry demonstrating that persistent abnormalities in calcium and phosphorus metabolism are common among dialysis patients but that vitamin D sterols are not used in many who would benefit from treatment. Conversely, vitamin D therapy is given commonly despite the presence of biochemical abnormalities that should otherwise preclude its use.
2. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004; 17:209-216. An overview of the major consequences of sHPT and its treatment on various organ systems.
3. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218. A retrospective analysis of a large database confirming earlier observations that elevated serum phosphorus levels are a risk factor for death from all causes and from cardiovascular causes among patients undergoing hemodialysis. Higher albumin-adjusted serum calcium concentrations were also associated with an increase in risk of death. When calcium, phosphorus and PTH levels were considered together, the increase in mortality risk attributable to disorders of mineral metabolism exceeded 17%.
4. Goodman WG. Calcimimetic agents for the treatment of secondary hyperparathyroidism. Semin Nephrol 2004; 24:460-463. A discussion of the calcium-sensing receptor, calcimimetic agents, and their mechanism of action, and a review of the acute biochemical responses to single oral doses of calcimimetic compounds in patients managed with hemodialysis. Results from early phase 2 clinical trials with cinacalcet are also summarized.
5. Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: a role for increased sensitivity to calcium. J Clin Invest 1989; 83:1349-1355.
6. Hamdy NA, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310:358-363.
7. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427-1432.
8. 2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36:562-565.
9. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:1-201.
10. Chen RA, Goodman WG. The role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004; 286:F1005-F1011. A detailed discussion of the calcium-sensing receptor and its physiological role as a modifier of various components of parathyroid gland function.
11. Parlitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52:3-9.
12. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139:4391-4396.
13. Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16:210-218. A description of annual parathyroidectomy rates between 1992 and 2002 among hemodialysis patients in the United States. Despite modest declines during the mid-1990s, parathyroidectomy rates in 2002 do not differ from those reported in 1992 despite the widespread use of parenteral doses of vitamin D sterols and large oral doses of calcium during this interval.
14. Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004; 44:1070-1076. A careful and detailed assessment of the pharmacokinetics of cinacalcet across a wide range of dosages.
15. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13:1017-1024.
16. Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 2004; 57:726-734. Evidence that the effect of cinacalcet to lower plasma PTH levels in patients with sHPT is not affected by hemodialysis procedures.
17. Block GA, Martin KJ, De Francisco ALM, et al. The calcimimetic cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516-1525. Results from clinical trials that enrolled more than 700 patients demonstrating the efficacy and safety of cinacalcet for treating sHPT among patients undergoing hemodialysis regularly. Substantial reductions in plasma PTH levels were associated with consistent, modest reductions in serum calcium and phosphorus levels.
18. Martin KJ, Jüppner H, Sherrard DJ, et al. First- and second-generation PTH assays to assess cinacalcet HCI (Sensipar/Mimpara) efficacy for secondary hyperparathyroidism. Kidney Int (in press).
19. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14:575-583.
20. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus product levels in hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2003; 63:248-254.
21. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 2005; 67:760-771. A summary of integrated results from several large phase 3 clinical trials indicating that treatment with cinacalcet improves the likelihood of managing sHPT within the K/DOQI guidelines.
22. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCI, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16:800-807. Results demonstrating that the efficacy of cinacalcet for treating sHPT does not differ between patients managed with peritoneal dialysis or hemodialysis.
23. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCI. Nephrol Dial Transplant (in press).
24. Garrett JE, Steffey ME, Nemeth EF. The calcium receptor agonist NPS R-568 suppresses PTH mRNA levels in cultured bovine parathyroid cells [abstract]. J Bone Miner Res 1995; 10:S387.
25. Silver J, Gaberman E, Naveh-Many T. The calcimimetic R-568 decreases PTH mRNA levels in rats with secondary hyperparathyroidism due to experimental uremia [abstract]. J Am Soc Nephrol 2003; 14:460A.
26. 2+ spike frequency can optimize gene expression. Nature 1998; 392: 936-941.
27. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998; 392:933-936.
28. Ho C, Conner DA, Pollak MR, et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995; 11:389-394.
29. Dardenne O, Prud'homme J, Hacking SA, et al. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003; 32: 332-340.
30. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D-1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279:16754-16766. Evidence which indicates that maintaining serum calcium levels within the normal range by dietary calcium supplementation precludes the development of parathyroid gland hyperplasia in mice that are homozygous for inactivating mutations of the vitamin D receptor. The same dietary manipulations are insufficient, however, to fully prevent parathyroid gland enlargement in mice that are homozygous for inactivating mutations of the gene that encodes 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1). The explanation for this discrepancy remains uncertain, although nongenomic mechanisms may contribute.
31. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: control of parathyroid cell growth via a calcium receptor. Clin Invest 1997; 100:2977-2983.
32. Guérin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1014-1021.
33. Ogata H, Ritz E, Odoni G, et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14:959-967.
34. Gunness-Hey M, Hock JM. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Relat Res 1984; 5:177-181.
35. Sjöden G, Lindgren JU, DeLuca HF. Antirachitic activity of 1α-hydroxyergocalciferol and 1α-hydroxycholecalciferol. J Nutr 1984; 114:2043-2046.
36. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
37. Ishii H, Wada M, Furuya Y, et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26:175-182.
38. Lien Y-HH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant (in press).